Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA6 | P23280 | 1/20 | 0.55 |
| ▸ | TPMT | P51580 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Veratric Acid Methyl Ester SCHEMBL3661352 | 0.98 | MAPT (0.73) | MAPTKMT2ATSHRCYP2C9CYP1A2 | |
| Veratric Acid Methyl Ester SCHEMBL29573244 | 0.89 | MAPT (0.86) | MAPTKMT2ATSHRCYP2C9CYP1A2 | |
| Veratric Acid Methyl Ester SCHEMBL2050732 | 0.89 | MAPT (0.86) | MAPTKMT2ATSHRCYP2C9CYP1A2 | |
| SCHEMBL12604683 | 0.86 | NOTUM (0.56) | MAPTKMT2ATSHRCYP2C9CA1 | |
| SCHEMBL31156002 | 0.85 | MAPT (0.51) | MAPTKMT2ACA1CA2CA12 | |
| SCHEMBL31265461 | 0.85 | MAPT (0.54) | MAPTKMT2ATSHRCA1CA2 | |
| Veratric Acid Methyl Ester SCHEMBL22717084 | 0.82 | MAPT (0.75) | MAPTKMT2ATSHRCYP2C9CYP1A2 | |
| SCHEMBL1781433 | 0.82 | SMN1; SMN2 (0.63) | MAPTKMT2ACYP2C9CYP1A2CYP3A4 | |
| Veratric Acid SCHEMBL3662041 | 0.81 | CA12 (0.75) | MAPTTSHRCYP2C9CYP1A2CYP3A4 | |
| SCHEMBL22026533 | 0.80 | KMT2A (0.50) | MAPTKMT2ATSHRCYP3A4CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575221-B2 | Derivatives of dimethylcurcumin | CONCERT PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8084464-B2 | Tetrahydroisoquinoline derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084464-B2 | Tetrahydroisoquinoline derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110257271-A1 | DERIVATIVES OF DIMETHYLCURCUMIN | CONCERT PHARMACEUTICALS, INC. | 2011-10-20 | — | — | US | disclosed |
| WO-2011116066-A1 | DERIVATIVES OF DIMETHYLCURCUMIN | CONCERT PHARMACEUTICALS, INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| US-7872013-B2 | Preparation and utility of opioid analgesics | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| EP-2231155-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | Concert Pharmaceuticals Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090192188-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090192188-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2009-07-30 | — | — | US | disclosed |
| WO-2009079637-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | WO | disclosed |
| US-20080045558-A1 | PREPARATION AND UTILITY OF OPIOID ANALGESICS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080039473-A1 | PREPARATION AND UTILITY OF SUBSTITUTED QUINAZOLINE COMPOUNDS WITH ALPHA-ADRENERGIC BLOCKING EFFECTS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192188-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | HCRTR2, HCRTR1, OXTR | MAPT 885/4885KMT2A 592/4885TSHR 932/4885 |
| US-20110257271-A1 | DERIVATIVES OF DIMETHYLCURCUMIN | UROD, UGT1A1, UGT1A3 | MAPT 4/4885KMT2A 1756/4885TSHR 4266/4885 |
| US-20080045558-A1 | PREPARATION AND UTILITY OF OPIOID ANALGESICS | OPRM1, OPRK1, OPRL1 | MAPT 203/4885KMT2A 2257/4885TSHR 1616/4885 |
| US-20080039473-A1 | PREPARATION AND UTILITY OF SUBSTITUTED QUINAZOLINE COMPOUNDS WITH ALPHA-ADRENERGIC BLOCKING EFFECTS | ADRB1, ADRB2, ADRB3 | MAPT 2648/4885KMT2A 3646/4885TSHR 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.